Who makes BI 2536 BS, intravenous?

BI 2536 BS, intravenous is developed by Boehringer Ingelheim.

What development phase is BI 2536 BS, intravenous in?

BI 2536 BS, intravenous is in Phase 1.

Last reviewed 2026-04-20 · How we verify

BI 2536 BS, intravenous

Boehringer Ingelheim · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	BI 2536 BS, intravenous
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BI 2536 BS, intravenous CI brief — competitive landscape report
BI 2536 BS, intravenous updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI